Intelligence Β· Patent portfolio
Regeneron Ireland Designated Patents
Full USPTO pharma patent portfolio for Regeneron Ireland Designated β grant dates, expiration, and drug cross-links.
- Patents
- 8,292
- Expiring β€24m
- 426
Quick answer
Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months β use filters for patent-cliff planning.
-
US 6899880
Porin B (PorB) as a therapeutic target for prevention and treatment of infection by chlamydia
expired -
US 6899892
Methods to reduce body fat
expired -
US 6897016
Alteration of sequence of a target molecule
expired -
US 6897196
pH sensitive lipids based on ortho ester linkers, composition and method
expired -
US 6894154
hKIS compositions and methods of use
expired -
US 6893643
Recombinant yellow fever virus and methods of use thereof
expired -
US 6893821
Agents that modulate DNA-PK activity and methods of use thereof
expired -
US 6894027
Stimulation of bone growth with thrombin peptide derivatives
expired -
US 6890949
Amino ceramide-like compounds and therapeutic methods of use
expired -
US 6890537
Antimicrobial theta defensins and methods of using same
expired -
US 6890552
Manufacturing therapeutic enclosures
expired -
US 6890738
Prolactin antagonists and uses thereof
expired -
US 6890721
Interleukin-1Ξ² converting enzyme like apoptotic protease-6
expired -
US 6890311
Methods for performing medical procedures within a breast duct
expired -
US 6887902
Anti-inflammatory method using gamma-aminobutyric acid (GABA) analogs
expired -
US 6887483
Non-toxic mutants of pathogenic gram-negative bacteria
expired -
US 6887468
Antibody kits for selectively inhibiting VEGF
expired -
US 6887489
Propionibacterium P-63 for use in direct fed microbials for animal feeds
expired -
US 6884596
Screening and therapeutic methods for promoting wakefulness and sleep
expired -
US 6884577
Methods for screening compounds for estrogenic activity
expired -
US 6884585
Induction of beta cell differentiation in human cells by stimulation of the GLP-1 receptor
expired -
US 6884431
Method for treating proliferative diseases with p27 and fusions thereof
expired -
US 6881857
Tricyclic diterpene derivatives
expired -
US 6881822
PSCA: prostate stem cell antigen and uses thereof
expired -
US 6878816
Vmp-like sequences of pathogenic Borrelia
expired -
US 6875419
Paramagnetic metal ion-based macrocyclic magnetization transfer contrast agents and method of use
expired -
US 6875849
Methods of recovering chaperone proteins and complexes thereof
expired -
US 6872385
Adjuvant preparation for the induction of specific immunity
expired -
US 6872387
Three-dimensional hydrogel/cell system
expired -
US 6872750
Modulating angiogenesis
expired -
US 6870042
Mutants of streptococcal toxin A and methods of use
expired -
US 6869568
Functional assay of high-density lipoprotein
expired -
US 6869777
Mini-dystrophin nucleic acid sequences
expired -
US 6866845
Compositions and methods for the treatment of sepsis
expired -
US 6867022
Replication deficient adenovirus vectors and methods of making and using them
expired -
US 6867353
Production method of recombinant rotavirus structural proteins and vaccine composition
expired -
US 6867289
Thio-modified aptamer synthetic methods and compositions
expired -
US 6867190
Methods of therapy with thrombin derived peptides
expired -
US 6864066
Epithelial protein lost in neoplasm (EPLIN)
expired -
US 6862890
Process for production of nanoparticles and microparticles by spray freezing into liquid
expired -
US 6864301
Preparation and use of photopolymerized microparticles
expired -
US 6864103
Phthalamide-lanthanide complexes for use as luminescent markers
expired -
US 6863895
Mycobacterial sulfation pathway proteins and methods of use thereof
expired -
US 6863888
Oncoprotein protein kinase
expired -
US 6861407
Methods of therapy with thrombin derived peptides
expired -
US 6861228
Modulating Robo: ligand interactions
expired -
US 6858402
System for discovering and producing polypeptides that cause TNF receptor shedding
expired -
US 6858409
Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors
expired
Frequently asked questions
How many patents does Regeneron Ireland Designated have?
8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Regeneron Ireland Designated patents expire?
426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources Β· Patent directory